Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Inclusion Criteria:

- Subject/legal representative is considered reliable and capable of adhering to the
protocol

- Subject has remained seizure free and completed the Maintenance Phase of the SP0993;
or subject has experienced 1 or more seizures on the first or second target dose
during the SP0993 Maintenance Phase

- Subject is expected to benefit from participation in SP0994 in the opinion of the
investigator

Exclusion Criteria:

- Subject is receiving any investigational drugs or using any experimental devices in
addition to LCM or CBZ-CR

- Subject experienced a seizure at the third target dose during the Evaluation Phase or
Maintenance Phase of the SP0993 study

- Subject is taking benzodiazepines for a non-epilepsy indication

- Subject meets a withdrawal criterion from the previous study SP0993

- Subject is experiencing an ongoing SAE from the previous study SP0993

- Subject has a lifetime history of suicide attempt (including an active attempt,
interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6
months as indicated by a positive response (Yes) to either Question 4 or Question 5 of
the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening. Or subject has a
positive response (Yes) to either Question 4 or Question 5 of the C-SSRS at Screening
in the "Since Last Visit" version